Navigation Links
Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
Date:2/6/2008

ALACHUA, Fla., Feb. 6 /PRNewswire-FirstCall/ -- Tutogen Medical, Inc. (Amex: TTG), a leading manufacturer of sterile biological implant products made from human (allograft) and animal (xenograft) tissue, today announced financial results for the first quarter of fiscal year 2008 ended December 31, 2007.

Highlights for the first quarter when compared to the previous year's first quarter include:

-- Total revenues increased 30%;

-- Revenues of dental products increased 27%;

-- Surgical specialty product revenues increased 73%;

-- U.S. revenues increased 30%;

-- International revenues increased 32%;

-- Excluding merger related costs, net income for the quarter would have

been $343,000 or $0.02 per fully diluted share, compared to a net

income of $361,000, or $0.02 per fully diluted share for the same

period last year.

As previously reported, on November 12, 2007, the Company entered into a merger agreement with Regeneration Technologies, Inc. The merger agreement provides that the Company's stockholders will receive 1.22 shares of Regeneration Technologies common stock for each share of the Company's stock that they own. Upon completion of the merger, the Company's stockholders will own approximately 45% of the combined company, on a fully diluted basis. The proposed merger is currently estimated to be completed later this month.

For the first quarter of fiscal year 2008, the Company reported revenues of $15.0 million compared to $11.5 million in the first quarter of the previous year; an increase of 30%. The gross margin for the first quarter was 54%, up from 50% in the fourth quarter. The first quarter gross margin of 54% was less than the g
'/>"/>

SOURCE Tutogen Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
4. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
5. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
6. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... MGB Biopharma at the ... MGB Biopharma, a biopharmaceutical company developing ... the major global problem of antibiotic resistance - ... (IV) formulation of MGB-BP-3, designed for the treatment of ... The intravenous formulation of MGB-BP-3 is currently in ...
(Date:6/1/2015)... 1, 2015  Turing Pharmaceuticals AG announced that life ... , MD, MSc,  has joined the company as ... Salinas, who holds a medical degree as well ... of significant accomplishments in the pharmaceutical industry, and ... Salinas has played a leadership role in numerous ...
(Date:6/1/2015)... CHICAGO , June 1, 2015 /PRNewswire/ ... robust Decipher® genomic analysis platform, successfully classified ... the genomic expression of certain biomarkers, including ... chemotherapy. Importantly, this unique genomic signature has ... responsiveness to neoadjuvant chemotherapy in patients with ...
(Date:6/1/2015)... June 1, 2015 Research ... addition of the "Global PDT Machine Industry ...        (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... is a professional and in-depth study on the ... report provides a basic overview of the industry ...
Breaking Biology Technology:MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Global PDT Machine Industry Report 2014 2
... cases from across the country to advance cancer care ... Inc ., the innovative healthcare company supporting the ... recognized as a Laureate by the International ... Program for its interactive patient management software ...
... Bulletin Board: RNER; "the Company"), which recently changed its ... new symbol to better reflect,its business. The new symbol: ... NASDAQ. , "The Company intends ... manufacturing business in China. The Company has,launched a new ...
... Infarction provided jointly by leading international cardiology societiesTOKYO ... Phase III TRITON-TIMI 38 study applied the new ... Infarction to the results of the study and ... undergoing percutaneous coronary intervention (PCI) and taking prasugrel, ...
Cached Biology Technology:US Oncology Named 2009 Laureate by IDG Computerworld Honors Program 2US Oncology Named 2009 Laureate by IDG Computerworld Honors Program 3US Oncology Named 2009 Laureate by IDG Computerworld Honors Program 4US Oncology Named 2009 Laureate by IDG Computerworld Honors Program 5RainEarth Inc. Changes Trading Symbol from GRKR to RNER 2Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 2Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 3Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 4Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 5Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial 6
(Date:5/22/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") announces ... pricing and making the Wocket generally available for $229 via ... of Marketing said, "We,ve extended the opportunity to take advantage ... To get your wocket at this special price, submit your ... June 1, you,ll receive a unique code that gives you ...
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
... the atomic structure of a powerful "molecular motor" that ... during their assembly, an essential step in their ability ... researchers, from Purdue University and The Catholic University of ... motor works. Parts of the motor move in sequence ...
... Scientists have identified an initiating molecular mechanism in ... Cell Press in the December 26th issue of ... about generation of damaging amyloid β (Aβ) plaques ... of developing new preventative and disease-modifying therapies for ...
... that the human brainonce thought to be a seriously ... make the best decisions possible with the information we ... of the journal Neuron ., Neuroscientists Daniel Kahneman ... their 1979 research that argued humans rarely make rational ...
Cached Biology News:Biologists learn structure, mechanism of powerful 'molecular motor' in virus 2Biologists learn structure, mechanism of powerful 'molecular motor' in virus 3Impaired energy metabolism linked with initiation of plaques in Alzheimer's brain 2Our unconscious brain makes the best decisions possible 2Our unconscious brain makes the best decisions possible 3
...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... Amplification Grade digests single- ... oligodeoxyribonucleotides. The specific activity ... I Amplification Grade is ... for absence of RNase ...
Biology Products: